Gli inibitori del recettore IIb/IIIa - Cuorediverona.it

More documents

Recommendations

Info

GUSTO V AMI GUSTO V - Trial Schematic (n = 16,588) ST ↑, lytic eligible, < 6 h ASA No Abciximab 2 x 10 U bolus (30’) Reteplase Standard Heparin: 5,000 U bolus followed by either 800 U/hr (pts < 80 kg) or 1,000 U/hr (pts ≥ 80 kg) infusion Abciximab 2 x 5 U bolus (30’) Reteplase Low Dose Heparin: 60 U/kg bolus followed by a 7 U/kg/h infusion 1º endpoint: mortality at 30 days 2º endpoint: clinical and safety events at 30 days Lancet Lancet 2001; 2001; 357:1905-14
GUSTO V AMI Primary Endpoint: 30 Days Mortality 5.9% 5.6% % Mortality • p = 0.43 for superiority • Non-Inferiority RR 0.95 (95% CI, 0.84-1.08) Std. Reteplase (n = 8260) Abciximab + ↓ Dose Reteplase (n = 8328) Days Lancet 2001; 357:1905-14
Page 1 and 2:
P come piastrine, come prezzemolo
Page 3 and 4:
Formazione del trombo nelle ACS sen
Page 5 and 6:
GP IIb-IIIa Inhibitors costituiscon
Page 8 and 9:
Cardiologia “De Gasperis”- Nigu
Page 10 and 11: Inibitori GPIIb/IIIa Artist’s con
Page 12: Characteristics of GP IIb/IIIa Inhi
Page 15 and 16: Patogenesi delle Sindromi Coronaric
Page 17 and 18: Sindromi Coronariche Acute ST-segme
Page 19: 8 16 Lancet 1997; 349:1429-35 35
Page 22 and 23: UA/NSTEMI Beneficio solo se PCI
Page 24 and 25: % of Patients IIb/IIIa Inhibition w
Page 26 and 27: GP IIb/IIIa Inhibitor During Medica
Page 28 and 29: Peterson E.D.et al.: Early use of g
Page 30 and 31: ISAR-COOL study - Pre-procedural ou
Page 32 and 33: CAPTURE Results by Troponin T Statu
Page 34 and 35: GP IIb/IIIa Inhibition in Diabetics
Page 36 and 37: Gli inibitori GP IIb/IIIa IIIa ridu
Page 38 and 39: ESC PCI guidelines 2004 2004 Recomm
Page 40 and 41: SCA: UA/NSTEMI L’applicazione del
Page 42 and 43: Coronarografia in base a età e TIM
Page 44 and 45: Sindromi Coronariche Acute ST-segme
Page 46 and 47: Occlusive thrombus contains Fibrin
Page 48 and 49: Abciximab Improves ST Res-90 min ST
Page 50 and 51: RAPPORT, ISAR 2, ADMIRAL, CADILLAC
Page 52 and 53: 5 GPIIb/IIIa inhibitors trials in P
Page 54 and 55: BMS and abciximab display a synergi
Page 56 and 57: Study design Inclusion Criteria: ST
Page 58 and 59: Multi-STRATEGY MULTIcenter evaluati
Page 62 and 63: IIb/IIIa Varie...ed eventuali
Page 64 and 65: IIb/IIIa e PCI: Nei pazienti stabil
Page 66: Conclusioni Glycoprotein IIb/IIIa I
show all

Gli inibitori del recettore IIb/IIIa - Cuorediverona.it

Create successful ePaper yourself

Delete template?

Save as template?